DOCSLIB.ORG

International Requisition Form

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
International Requisition Form PleasePlease place place collection collection kit kit INTERNATIONAL barcode here. REQUISITION FORM barcode here. REQUISITION FORM 123456-2-X PLEASE COMPLETE ALL FIELDS. REQUISITION FORMS SUBMITTED WITH MISSING INFORMATION MAY CAUSE A DELAY IN TURNAROUND TIME OF THE TEST. PLEASE COMPLETE ALL FIELDS. REQUISITION FORMS SUBMITTED WITH MISSING INFORMATION MAY CAUSE A DELAY IN TURNAROUND TIME OF THE TEST. PATIENT INFORMATION ORDERING CLINICIAN INFORMATION PATIENT NAME (LAST, FIRST) NAME OF ORGANIZATION 1 PatIENT INFORmatION (Must be completed in English) 2 ORDERING CLINICIAN (Must be completed in English) DATE OF BIRTH (MM/DD/YYYY) Organization (Clinic, Hospital, or Lab): Patient Name (Last, First): ADDRESS TELEPHONE CITYPatient DOB (DD/MM/YYYY): STATE ZIP CODE ORDERINGLIMS-ID: CLINICIAN TELEPHONE EMAIL Patient Street Address: Telephone: I would like to receive emails about my test from Natera Y N City: Country: Ordering Clinician: PATIENT MALE OR FEMALE? M-V26.34 F-V26.31 PATIENT PREGNANT? Y-V22.1 N DATE OF SAMPLE COLLECTION (MM/DD/YY):_____________________________ Telephone: Email: PAYMENT PLEASEPatient CHECK male orONE: female: M F BILL INSURANCE BILL CLINIC BILL CLINIC/CA Prenatal SELF-PAY Patient pregnant? Program YPDC N INSURANCE COMPANY (Please enclose a photocopy (front and CLINICIAN INFORMED CONSENT MEMBERDate of ID sample collectionSUBSCRIBER (DD/MM/YYYY): NAME (if different than patient) back) or all relevant insurance cards) If you would like the results of this case to be sent to an additional FAX fax number other than what is indicated on your setup form, please IF SELF-PAY, CHECK CARD TYPE: VISA MASTER CARD AMEX DISCOVER provide the fax number. NAME ON CARD CREDIT CARD NUMBER STATEMENT OF INFORMED CONSENT I confirm that this patient has been informed about the details including the risks, benefits and limitations of the 3 genetic test(s) ordered on this form, and has given consent for the testing as may be required under applicable law. CVV EXPIRATIONPAYMEN T(MM/YYYY) PATIENT SIGNATURE Physician/Authorized Signature ______________________________________ Disposition or Retention of Samples Bill Clinic Self-Pay PATIENT ACKNOWLEDGEMENTLaboratory (Reseller) represents and confirms that the patient has given informed I confirmIf self thatpay, I have complete been informed the followingabout the details information: of the tests ordered for me by my provider including one or more of the following: Panoramaconsent prenatal in compliancescreen, Horizon genetic with carrierapplicable screen, or law Anora to products Natera’s of conception following test, includingsample their disposition (its) risks, benefits and limitations, and I voluntarily consent to testing. I understand I am financially responsible for services performed; including any copayments,or retention deductibles, policy: or other PATIENT amounts deeme UNDERSTANDSd ‘patient responsibility’ AND prior toCONSENTS test services being THAT: performed. (i) her/his I authorizeCheck Natera card or other type: provider to submit VISA claims to my MASTERCARD medical insurance on my behalf, AMEX if applicable, with DISCOVER all benefits of my plan made payablesample directly will to Natera be sentor other to provider. the UnitedNOTE: Patients States tested for pursuant performance to California’s Prenatalof the Screeningtest; (ii) Program Natera will not be billed for the ‘Panorama Prenatal Panel’ when 22q11.2 is opted out. may retain the patient’s leftover, de-identified samples to use for medical and Natera may keep my leftover de-identified samples for ongoing research and development. I and my heirs will not receive any payments, benefits, or rights to any resulting products or discoveries. If I do not want my de-identified sample used, I may send a requestName in writing on card: to Natera at Attn: Sample Retention, 201 Industrial Rd, Ste 410, San Carlos, CA 94070, or an email to [email protected] within 60 days advancement, after test results have research been issued & and development, my sample will be productdestroyed. NOTE:validation All samples and from quality patients residing in the state of New York will be destroyed within 60 days after the sample has been collected. assurance, independently or in collaboration with third-party partners, either in PatientCredit Signaturecard number:__________________________________________________________________________________________________________________or outside the United States; and (iii) patient and patient’s Date_____________________ heirs will not receive any payments, benefits, or rights to any resulting products or discoveries. If the patient does not want his or her de-identified sample used, the patient may send CCV: TEST ORDERING Expiration (DD/MM/YYYY): (SEE TEST DESCRIPTIONS SHEET FOR TEST EXPLANATIONS) a request in writing to the clinic or laboratory where the test was ordered within TM TM TM PANORAMA PRENATAL SCREEN HORIZON CARRIER60 days SCREEN after test results have beenANORA issued, andMISCARRIAGE such clinic or laboratory TEST will work Patient signature: PANORAMA PANEL OPTIONS: HORIZON PANEL OPTIONS:with Natera to destroy theANORA sample. OPTION: PANORAMA PRENATAL PANEL 10 mL 10 mL Number of conditions screened for ANORA MISCARRIAGE TEST 6 mL CODES FOR ALL PANELS: V77.6, V78.2, V77.7, V78.3, 783.9 Chromosomes 13, 18, 21, X and Y; Triploidy; 22q.11.2 deletion DATE OF PREGNANCY LOSS (MM/DD/YY): _________________ 4 HORIZONTM TEST ORDERING (SEE TEST DES4 (SMA,CRI PTCF, IONSFRAGILE S X,H EEDMD)T FOR TEST E10XPLA mL NATIONS) I DO NOT WANT 22Q.11.2 27 (PAN-ETHNIC STANDARD) GESTATIONAL AGE AT LOSS (WEEKS): ____________________ or PANORAMA EXTENDED PANEL 10 mL 10 mL 106 (COMPREHENSIVE JEWISH) THIS PREGNANCY WAS: PanoramaHORIZON Prenatal PANE PanelL O PTPLUSIONS 4 additional: microdeletions 137 (PAN-ETHNIC LARGE) Family history of2mL intellectual SINGLETON disabilities TWINS TRIPLETS OTHER 274 (PAN-ETHNIC EXTENDED) For any panel or CF I WANT FETAL SEX REPORTED IF MULTIPLES: IDENTICAL NON-IDENTICAL UNKNOWN Number of conditions screened for ADD TAY-SACHS ENZYME Familyor SMA history single optionsof other diseases of the musculoskeletal system and WAS AN EGG OR SURROGATE USED: Y N 4 (SMA, CF, Fragile X, DMD) (Available for Horizon 27, 106, 137,connective 274) tissue MATERNAL HEIGHT: __________ FEET _________ INCHES IF D&C, HOSPITAL OR SURGERY CENTER NAME: MATERNAL 27 (Pan-ethnic WEIGHT: Standard)_________ POUNDS SINGLE OPTIONS: Family history of carrier ______________________________________________________of genetic disease 10 mL or 10 mL GESTATIONAL 106 (Comprehensive AGE:__________ Jewish)_ WEEKS _______ DAYS If no panels are selected Family history of other specified conditions SAMPLE TYPE: FRESH PARAFFIN IS THIS A TWIN OR MULTIPLE GESTATION PREGNANCY? Y N CF-V77.6 SMA -V77.6, V78.2, V77.7, V78.3 137 (Pan-ethnic Large) TAY-SACHS ENZYME -V77.6, V78.2, Encounter V77.7, V78.3for genetic counselingPlease submit a parental blood sample. If egg donor Patient must be at least 9 weeks gestational age 274 (Pan-ethnic Extended) (Saliva is not available for Enzyme; requires an additional tube when was used, please submit sample from biological father. ETHNICITY: DUE DATE (MM/DD/YY):______________ ordered with a panel) Both parental samples are needed for paraffin testing. WASSample AN EGG requirement DONOR OR for SURROGATE Horizon Panel USED? Options: Y N Northern European (e.g. British, German, Irish) ETHNICITY: BLOOD SAMPLE COLLECTED IS 1THE 10mL MOTHER Lavender A KNOWN-top MICRODELETIONK2 EDTA blood CARRIER?tube Y N Southern European (e.g. Italian, Mediterranean, Greek) AFRICAN AMERICAN MEDITERRANEAN FROM (NAME): _____________________________________ WILL THE FATHER'S SAMPLE BE SUBMITTED WITH THIS CASE? E ASIAN SE ASIAN Ashkenazi Jewish BIOLOGICAL MOTHER BIOLOGICAL FATHER PLY EASEN IFSE YES,LECT NAME:____________________ ALL APPROPRIATE CL DOB:___________INICAL INDICATIONS CAUCASIAN: ASHKENAZI JEWISH East Asian (e.g. Chinese, KorGESTATIONALean, Japanese) CARRIER Father’s Screening sample formust other be submittedmetabolic indisorders same kit SEPHARDIC JEWISH FRENCH CANADIAN South Asian* (e.g. Indian, Pakistani) Nonprocreative screening for genetic disease carrier status HISPANIC/LATIN AMERICAN PLEASE SELECT ALL APPROPRIATE CLINICAL PLEASE CHECK ALL APPROPRIATE OTHER: _______________________________________ South-East Asian (e.g. Filipino,INDICATIONS: Vietnamese) Other screening for genetic and chromosomal anomalies CLINICAL INDICATIONS: IS THE PATIENT CURRENTLY USING African or African American RECURRENT LOSS, NOT PREGNANT- 629.81 Screening for other disorder ADVANCED MATERNAL AGE, 1ST PREGNANCY-659.53 / V23.81 HORMONAL MEDICATIONS? Hispanic LOSS WITH RETENTION AFTER 22 WKS - 656.40 ADVANCED Female for MATERNAL testing for AGE,genetic NOT disease 1ST PREGNANCY-659.63 carrier status for procreative / management Y-V22.1 N UNSPECIFIED ABORTION WITHOUT MENTION OF Middle Eastern* V23.82 Male for testing for genetic disease carrier status for procreative managementPLEASE SELECT ALL APPROPRIATE CLINICAL COMPLICATION - 637.90 Other/mixed Caucasian* ABNORMAL/POSITIVE Pregnant state, incidental SERUM SCREENING-796.5 INDICATIONS: LOSS WITH RETENTION PRIOR TO 22 WKS - 632 ANEUPLOIDY IN MOTHER, FETAL ANEUPLOIDY-655.13 FAMILY HISTORY (GENETIC DISEASE)Is the patient -V18.9 currently using hormonal medications? Supervision of normal 1st pregnancy, 1st trimester BLIGHTED OVUM [OTHER ABNORMAL POC] - 631.8 SUPERVISION OF HIGH-RISK
Load more

Recommended publications
  • Federal Register/Vol. 69, No. 194/Thursday, October 7, 2004
    Federal Register / Vol. 69, No. 194 / Thursday, October 7, 2004 / Rules and Regulations 60083 Regulations Branch, Office of drawback requested on the drawback war are decided fairly, consistently, and Regulations and Rulings, U.S. Customs entry. This is determined as follows: based on all available medical and Border Protection. However, * * * * * information concerning the diseases personnel from other offices I 4. In § 191.171, a new paragraph (c) is associated with detention or internment participated in its development. added to read as follows: as a prisoner of war. DATES: List of Subjects in 19 CFR Part 191 This interim final rule is § 191.171 General; drawback allowance. effective October 7, 2004. Comments Claims, Commerce, CBP duties and * * * * * must be received on or before November inspection, Drawback. (c) Merchandise processing fees. In 8, 2004. cases where the requirements of Amendments to the Regulations ADDRESSES: Written comments may be paragraph (b)(1) of this section have submitted by: mail or hand-delivery to I For the reasons stated above, part 191 been met, merchandise processing fees Director, Regulations Management of the CBP Regulations (19 CFR part 191) will be eligible for drawback. (00REG1), Department of Veterans is amended as follows: Approved: October 4, 2004. Affairs, 810 Vermont Ave., NW., Room Robert C. Bonner, 1068, Washington, DC 20420; fax to PART 191 — DRAWBACK Commissioner, U.S. Customs and Border (202) 273–9026; e-mail to I 1. The general authority citation for Protection. [email protected]; or, through part 191 continues to read as follows: Timothy E. Skud, http://www.Regulations.gov. Comments Deputy Assistant Secretary of the Treasury.
    [Show full text]
  • Fusion of Multiple Heterogeneous Networks for Predicting Circrna
    www.nature.com/scientificreports OPEN Fusion of multiple heterogeneous networks for predicting circRNA- disease associations Received: 22 January 2019 Lei Deng1, Wei Zhang1, Yechuan Shi1 & Yongjun Tang2 Accepted: 18 June 2019 Circular RNAs (circRNAs) are a newly identifed type of non-coding RNA (ncRNA) that plays crucial roles Published: xx xx xxxx in many cellular processes and human diseases, and are potential disease biomarkers and therapeutic targets in human diseases. However, experimentally verifed circRNA-disease associations are very rare. Hence, developing an accurate and efcient method to predict the association between circRNA and disease may be benefcial to disease prevention, diagnosis, and treatment. Here, we propose a computational method named KATZCPDA, which is based on the KATZ method and the integrations among circRNAs, proteins, and diseases to predict circRNA-disease associations. KATZCPDA not only verifes existing circRNA-disease associations but also predicts unknown associations. As demonstrated by leave-one-out and 10-fold cross-validation, KATZCPDA achieves AUC values of 0.959 and 0.958, respectively. The performance of KATZCPDA was substantially higher than those of previously developed network-based methods. To further demonstrate the efectiveness of KATZCPDA, we apply KATZCPDA to predict the associated circRNAs of Colorectal cancer, glioma, breast cancer, and Tuberculosis. The results illustrated that the predicted circRNA-disease associations could rank the top 10 of the experimentally verifed associations. Circular RNA (circRNA) is a class of non-coding RNA recently discovered. Unlike linear RNA, circRNA forms a continuous cycle of covalent closures and is highly represented in the eukaryotic transcriptome. Previous research has found thousands of prototype circRNAs in human, mouse and nematode cells1–4.
    [Show full text]
  • European Conference on Rare Diseases
    EUROPEAN CONFERENCE ON RARE DISEASES Luxembourg 21-22 June 2005 EUROPEAN CONFERENCE ON RARE DISEASES Copyright 2005 © Eurordis For more information: www.eurordis.org Webcast of the conference and abstracts: www.rare-luxembourg2005.org TABLE OF CONTENT_3 ------------------------------------------------- ACKNOWLEDGEMENTS AND CREDITS A specialised clinic for Rare Diseases : the RD TABLE OF CONTENTS Outpatient’s Clinic (RDOC) in Italy …………… 48 ------------------------------------------------- ------------------------------------------------- 4 / RARE, BUT EXISTING The organisers particularly wish to thank ACKNOWLEDGEMENTS AND CREDITS 4.1 No code, no name, no existence …………… 49 ------------------------------------------------- the following persons/organisations/companies 4.2 Why do we need to code rare diseases? … 50 PROGRAMME COMMITTEE for their role : ------------------------------------------------- Members of the Programme Committee ……… 6 5 / RESEARCH AND CARE Conference Programme …………………………… 7 …… HER ROYAL HIGHNESS THE GRAND DUCHESS OF LUXEMBOURG Key features of the conference …………………… 12 5.1 Research for Rare Diseases in the EU 54 • Participants ……………………………………… 12 5.2 Fighting the fragmentation of research …… 55 A multi-disciplinary approach ………………… 55 THE EUROPEAN COMMISSION Funding of the conference ……………………… 14 Transfer of academic research towards • ------------------------------------------------- industrial development ………………………… 60 THE GOVERNEMENT OF LUXEMBOURG Speakers ……………………………………………… 16 Strengthening cooperation between academia
    [Show full text]
  • NGS Sequencing May Be Wes Or Targeted
    Guidelines for diagnostic next generation sequencing 2 December 2014 LS, This is the final draft version of a document on the diagnostic use of NGS that we wish to publish on behalf of EuroGentest. The first version of this document was drafted by a small number of people. It was subjected to peer review by the participants to the Nijmegen meeting, November 21-22, 2013. The document is ready for circulation and public consultation. Hence, it will be posted on the EuroGentest website for a few weeks. The procedure is in line with the process that other policy documents, generated by the European Society of Human Genetics, have to follow: the background document is posted and an invitation to comment is sent to the membership of the Society. Thereafter, a final version of the guidelines will be published in the European Journal for Human Genetics. Of course, guidelines in a fast moving field can never be definitive, hence a system will be put in place to update them on a regular basis. I wish to thank all the colleagues who have contributed to the development of the guidelines and the generation of the document. The members of the working group will be co-authors on the paper, the contribution of the other participants to the Nijmegen meeting will be acknowledged. We believe that the document is timely, even though we have been slow in finalizing the editorial work. By posting it now, everybody who is interested in the guidelines or eagerly seeking advice will be able to consult the workgroup’s viewpoints and recommendations.
    [Show full text]
  • Environmental Nutrition: Redefining Healthy Food
    Environmental Nutrition Redefining Healthy Food in the Health Care Sector ABSTRACT Healthy food cannot be defined by nutritional quality alone. It is the end result of a food system that conserves and renews natural resources, advances social justice and animal welfare, builds community wealth, and fulfills the food and nutrition needs of all eaters now and into the future. This paper presents scientific data supporting this environmental nutrition approach, which expands the definition of healthy food beyond measurable food components such as calories, vitamins, and fats, to include the public health impacts of social, economic, and environmental factors related to the entire food system. Adopting this broader understanding of what is needed to make healthy food shifts our focus from personal responsibility for eating a healthy diet to our collective social responsibility for creating a healthy, sustainable food system. We examine two important nutrition issues, obesity and meat consumption, to illustrate why the production of food is equally as important to consider in conversations about nutrition as the consumption of food. The health care sector has the opportunity to harness its expertise and purchasing power to put an environmental nutrition approach into action and to make food a fundamental part of prevention-based health care. but that it must come from a food system that conserves and I. Using an Environmental renews natural resources, advances social justice and animal welfare, builds community wealth, and fulfills the food and Nutrition Approach to nutrition needs of all eaters now and into the future.i Define Healthy Food This definition of healthy food can be understood as an environmental nutrition approach.
    [Show full text]
  • Regulations for Disease Reporting and Control
    Department of Health Regulations for Disease Reporting and Control Commonwealth of Virginia State Board of Health October 2016 Virginia Department of Health Office of Epidemiology 109 Governor Street P.O. Box 2448 Richmond, VA 23218 Department of Health Department of Health TABLE OF CONTENTS Part I. DEFINITIONS ......................................................................................................................... 1 12 VAC 5-90-10. Definitions ............................................................................................. 1 Part II. GENERAL INFORMATION ............................................................................................... 8 12 VAC 5-90-20. Authority ............................................................................................... 8 12 VAC 5-90-30. Purpose .................................................................................................. 8 12 VAC 5-90-40. Administration ....................................................................................... 8 12 VAC 5-90-70. Powers and Procedures of Chapter Not Exclusive ................................ 9 Part III. REPORTING OF DISEASE ............................................................................................. 10 12 VAC 5-90-80. Reportable Disease List ....................................................................... 10 A. Reportable disease list ......................................................................................... 10 B. Conditions reportable by directors of
    [Show full text]
  • LIST of OCCUPATIONAL DISEASES (Revised 2010)
    LIST OF OCCUPATIONAL DISEASES (revised 2010) Identification and recognition of occupational diseases: Criteria for incorporating diseases in the ILO list of occupational diseases Occupational Safety and Health Series, No. 74 List of occupational diseases (revised 2010) Identification and recognition of occupational diseases: Criteria for incorporating diseases in the ILO list of occupational diseases INTERNATIONAL LABOUR OFFICE • GENEVA Copyright © International Labour Organization 2010 First published 2010 Publications of the International Labour Office enjoy copyright under Protocol 2 of the Universal Copyright Convention. Nevertheless, short excerpts from them may be reproduced without authorization, on condition that the source is indicated. For rights of reproduction or translation, application should be made to ILO Publications (Rights and Permissions), International Labour Office, CH-1211 Geneva 22, Switzerland, or by email: pubdroit@ ilo.org. The International Labour Office welcomes such applications. Libraries, institutions and other users registered with reproduction rights organizations may make copies in accordance with the licences issued to them for this purpose. Visit www.ifrro.org to find the reproduction rights organization in your country. ILO List of occupational diseases (revised 2010). Identification and recognition of occupational diseases: Criteria for incorporating diseases in the ILO list of occupational diseases Geneva, International Labour Office, 2010 (Occupational Safety and Health Series, No. 74) occupational disease / definition. 13.04.3 ISBN 978-92-2-123795-2 ISSN 0078-3129 Also available in French: Liste des maladies professionnelles (révisée en 2010): Identification et reconnaissance des maladies professionnelles: critères pour incorporer des maladies dans la liste des maladies professionnelles de l’OIT (ISBN 978-92-2-223795-1, ISSN 0250-412x), Geneva, 2010, and in Spanish: Lista de enfermedades profesionales (revisada en 2010).
    [Show full text]
  • ICD-10 International Statistical Classification of Diseases and Related Health Problems
    ICD-10 International Statistical Classification of Diseases and Related Health Problems 10th Revision Volume 2 Instruction manual 2010 Edition WHO Library Cataloguing-in-Publication Data International statistical classification of diseases and related health problems. - 10th revision, edition 2010. 3 v. Contents: v. 1. Tabular list – v. 2. Instruction manual – v. 3. Alphabetical index. 1.Diseases - classification. 2.Classification. 3.Manuals. I.World Health Organization. II.ICD-10. ISBN 978 92 4 154834 2 (NLM classification: WB 15) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • FAQ REGARDING DISEASE REPORTING in MONTANA | Rev
    Disease Reporting in Montana: Frequently Asked Questions Title 50 Section 1-202 of the Montana Code Annotated (MCA) outlines the general powers and duties of the Montana Department of Public Health & Human Services (DPHHS). The three primary duties that serve as the foundation for disease reporting in Montana state that DPHHS shall: • Study conditions affecting the citizens of the state by making use of birth, death, and sickness records; • Make investigations, disseminate information, and make recommendations for control of diseases and improvement of public health to persons, groups, or the public; and • Adopt and enforce rules regarding the reporting and control of communicable diseases. In order to meet these obligations, DPHHS works closely with local health jurisdictions to collect and analyze disease reports. Although anyone may report a case of communicable disease, such reports are submitted primarily by health care providers and laboratories. The Administrative Rules of Montana (ARM), Title 37, Chapter 114, Communicable Disease Control, outline the rules for communicable disease control, including disease reporting. Communicable disease surveillance is defined as the ongoing collection, analysis, interpretation, and dissemination of disease data. Accurate and timely disease reporting is the foundation of an effective surveillance program, which is key to applying effective public health interventions to mitigate the impact of disease. What diseases are reportable? A list of reportable diseases is maintained in ARM 37.114.203. The list continues to evolve and is consistent with the Council of State and Territorial Epidemiologists (CSTE) list of Nationally Notifiable Diseases maintained by the Centers for Disease Control and Prevention (CDC). In addition to the named conditions on the list, any occurrence of a case/cases of communicable disease in the 20th edition of the Control of Communicable Diseases Manual with a frequency in excess of normal expectancy or any unusual incident of unexplained illness or death in a human or animal should be reported.
    [Show full text]
  • 10Th Anniversary of the Human Genome Project
    Grand Celebration: 10th Anniversary of the Human Genome Project Volume 3 Edited by John Burn, James R. Lupski, Karen E. Nelson and Pabulo H. Rampelotto Printed Edition of the Special Issue Published in Genes www.mdpi.com/journal/genes John Burn, James R. Lupski, Karen E. Nelson and Pabulo H. Rampelotto (Eds.) Grand Celebration: 10th Anniversary of the Human Genome Project Volume 3 This book is a reprint of the special issue that appeared in the online open access journal Genes (ISSN 2073-4425) in 2014 (available at: http://www.mdpi.com/journal/genes/special_issues/Human_Genome). Guest Editors John Burn University of Newcastle UK James R. Lupski Baylor College of Medicine USA Karen E. Nelson J. Craig Venter Institute (JCVI) USA Pabulo H. Rampelotto Federal University of Rio Grande do Sul Brazil Editorial Office Publisher Assistant Editor MDPI AG Shu-Kun Lin Rongrong Leng Klybeckstrasse 64 Basel, Switzerland 1. Edition 2016 MDPI • Basel • Beijing • Wuhan ISBN 978-3-03842-123-8 complete edition (Hbk) ISBN 978-3-03842-169-6 complete edition (PDF) ISBN 978-3-03842-124-5 Volume 1 (Hbk) ISBN 978-3-03842-170-2 Volume 1 (PDF) ISBN 978-3-03842-125-2 Volume 2 (Hbk) ISBN 978-3-03842-171-9 Volume 2 (PDF) ISBN 978-3-03842-126-9 Volume 3 (Hbk) ISBN 978-3-03842-172-6 Volume 3 (PDF) © 2016 by the authors; licensee MDPI, Basel, Switzerland. All articles in this volume are Open Access distributed under the Creative Commons License (CC-BY), which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications.
    [Show full text]
  • Section 1 ABOUT the DISEASE
    MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH GUIDE TO SURVEILLANCE, REPORTING, AND CONTROL Hepatitis A July 2016 | Page 1 of 14 Section 1 ABOUT THE DISEASE A. Etiologic Agent Hepatitis A is caused by the hepatitis A virus (HAV), an RNA virus in the picornavirus family. B. Clinical Description The onset of hepatitis A is usually abrupt, with fever, malaise, anorexia, nausea, and abdominal discomfort; some individuals may experience diarrhea. Jaundice (yellowing of the skin or whites of the eye, dark urine, and clay colored stool) may follow a few days later. Jaundice is present in 70% or more of adults with hepatitis A but is rare in infected children. Serum aminotransferase levels (ALT and AST) are often elevated. Infections vary from asymptomatic (common in young children) to disabling illness lasting several months. Generally, symptom severity increases with increasing age. The duration of symptomatic hepatitis A is typically less than two months. Prolonged, relapsing hepatitis for up to six months can occur in some cases. Hepatitis A is rarely fatal and has no chronic carrier state. The elderly and persons with chronic liver disease (including chronic hepatitis B or C) are at greater risk of severe hepatitis A and death. Hepatitis A is clinically indistinguishable from other types of hepatitis. It must be diagnosed through laboratory testing. C. Vectors and Reservoirs Humans with active infections (symptomatic or not) are the reservoir for this disease. Rarely, non-human primates can serve as a reservoir. D. Modes of Transmission The principal mode of transmission is direct or indirect person-to-person spread via the fecal-oral route.
    [Show full text]
  • Anne Frank: Nutrition - Anne Frank and Me
    Anne Frank: Nutrition - Anne Frank and Me Summary Quotation: 'In the twenty one months that we've spent here we have been through a good many 'food cycles'...periods in which one has nothing else to eat but one particular dish or kind of vegetable. We had nothing but endive for a long time, day in, day out, endive with sand, endive without sand, stew with endive, boiled or 'en casserole;' then it was spinach, and after that followed kohlrabi, salsify, cucumbers, tomatoes, sauerkraut, etc., each according to the season.' -Anne Frank (April 3, 1944) Time Frame 4 class periods of 45 minutes each Group Size Pairs Life Skills Thinking & Reasoning Materials Computer hardware and software, including a diet analysis program such as MACDINE II or Nutritionist III Older programs such as MECC Elementary Volume 13 may be available in schools but are no longer current. Optional: VCR and monitor for news clips showing current information on nutrition issues related to feeding the homeless in the U.S., or international stories from Somalia, Bosnia-Herzogovina, etc., newspaper and or/ magazine articles for these issues. Intended Learning Outcomes Students will compare/contrast past and present discrimination. Instructional Procedures See preface material from 'Anne Frank in the World, 1929 - 1945 Teacher Workbook.' Read the quotation and/or other sections about food in the Secret Annex from Anne Frank's Diary. Ask students to predict some of the possible consequences of this situation. Have them brainstorm a list of diseases or conditions related to nutrition or food deficiencies. They will probably know anorexia, bulimia, osteoporosis and may add rickets or scurvy.
    [Show full text]